Prazoto IV contains pantoprazole. It is a drug belonging to a class known as proton pump inhibitors. It helps in reduction of acid in stomach. It produces immediate relief in heart burns. It is potent inhibitor in gastric acid reduction.
- Short term treatment for erosive esophagitis associated with GERD
- It is indicated for the maintenance of healing of erosive esophagitis
- Reduction in the symptoms of heartburn in day and night time
- In hypersecretory symptoms
- Zollinger-Ellison syndrome
- Short term treatment in patients of five year and above
- GERD
Once daily by intravenous infusion for 7 to 10 days.
It produces its action by formation of covalent bond to two sides of the (H+,K+)- ATPase enzyme system on the secretory surface of the gastric parietal cells is the final step in gastric acid production which is inhibited by pantoprazole.
Absorption:
It is well absorbed in body. It undergoes first pass metabolism with bioavailability of 77% .
Distribution:
The drug protein binding is 98%. The metabolism of the drug through cytochrome P450 (CYP) in liver. The CYP2C19 causes demethylation and subsequent sulfation. The metabolism of the drug also includes oxidation by CYP3A4.
Excretion:
Elimination of the drug through urine is about 71% and 18% through feces by biliary excretion.
- Patient with hypersensitivity reaction
- Anaphylaxis
- Anaphylactic shock
- Angioedema
- Bronchspasm
- Acute intestinal nephritis
- Urticaria
- Long term use causes acute interstitial nephritis
- Long treatment with acid suppressing drug causes malabsorption
- Patient with high risk of Clostridium difficileassociated diarrhea treating with acid suppressing drug
- Can increase the risk of osteoporosis
- Should not be prescribed for long term treatment because it can even cause gastrointestinal tumors.
